



Fengzhi Li

Canget BioTekpharma LLC, USA

**Biography:**

In the past more than a decade, I have been running a research laboratory for cancer basic and translational research at Roswell Park Cancer Institute (RPCI, [www.roswellpark.org](http://www.roswellpark.org)), the first cancer center in the history of the United States founded at 1898. Since we have breakthrough findings in anticancer drug discovery and development, a new biotech and biopharma company was spun off from RPCI (Buffalo, New York). As the Founder and Chief Scientific Officer (CSO) of Canget BioTekpharma ([www.canget-biotek.com](http://www.canget-biotek.com)) and a lab head at RPCI, I have relevant experience, expertise, leadership and motivation necessary to oversee relevant R&D projects. I have been involved in the initial characterization of the regulation, expression, and function of the survivin gene in cancer cells since my postdoctoral training at Yale University Medical School. Over the past more than a decade since I have established my own lab at Roswell Park Cancer Institute (RPCI), my research team and I have accomplished various research projects. While the studies in my research lab centered around the antiapoptotic protein survivin in the inhibitor of apoptosis (IAP) family relevant to cancer, my research lab also studies other protein members in the IAP and Bcl-2 families, and explores cancer cell survival signaling pathways, anticancer drug resistance, and combination therapies, etc.

Through these studies and research activities, I have accumulated a background in and research experience related to drug action mechanism, apoptosis control, and drug/radiation resistance due to the aberrant expression of survivin and other antiapoptotic protein members in the IAP and Bcl-2 families. My research lab is highly productive and I have a strong publication record, having published over 40 peer-reviewed papers in the antiapoptotic research field and in areas relevant to this project, since I set up my own lab a decade ago in 2001. As a result of our persistent efforts in the past more than a decade on basic and translational cancer research at RPCI, we have filed several patents. Two of these patents have been licensed from RPCI into Canget BioTekpharma.

The research in my academic laboratory has been supported by federal agencies (NIH/NCI, DOD) and various public/private foundations. He was reported to be in the top 5% of cited authors for the Journals relevant to Biology and Biochemistry. Dr. Li is a grant reviewer for a number of countries including the United States, Singapore, UK, Israel, Ireland, and Hong Kong of China. He is also an ad hoc reviewer for many scientific journals. He is an editorial board member on several scientific journals. He is also a member of a number of scientific societies including American Society for Biochemistry and Molecular Biology (ASBMB), American Association for the Advancement of Science (AAAS), American Association for Cancer Research (AACR) and the New York Academy of Sciences (NYAS).

Copyright © 2013 Engli. All rights reserved.

Microsoft Internet Explorer is recommended if the page is not displayed properly !